Anticoagulants

Key Points

• Anticoagulants are high-alert medications (ISMP) — require independent double-checks and strict monitoring protocols
• Anticoagulants prevent new clot formation but do NOT dissolve existing clots (thrombolytics dissolve clots)
• Heparin: Antidote is protamine sulfate; monitor aPTT (goal: 1.5–2.5× baseline)
• Warfarin: Antidote is vitamin K; monitor INR (therapeutic range: 2.0–3.5 depending on indication)
• DOACs (rivaroxaban, apixaban, dabigatran): No routine monitoring required; reversal agents available
• All anticoagulants carry significant bleeding risk — monitor for signs of hemorrhage
• Pediatric CHD populations have additional thrombosis drivers (turbulent/restricted flow, heart failure, arrhythmias, polycythemia, central lines/shunts, perioperative factors) that may require anticoagulation planning.
• In pulmonary-hypertension subgroups, anticoagulation may be avoided because bleeding and hemoptysis risk can outweigh benefit; if used, dosing is typically conservative with close specialist follow-up.
• In pregnancy-associated DVT pathways, LMWH is typically preferred; warfarin and most oral anticoagulants are generally avoided antenatally because of fetal risk.

Drug Class Overview

Anticoagulants prevent clot formation by inhibiting specific steps in the coagulation cascade. They are used to treat and prevent deep vein thrombosis (DVT), pulmonary embolism (PE), stroke in atrial fibrillation, and complications of cardiac valve replacement. Because of their narrow therapeutic index and high bleeding risk, anticoagulants are classified as high-alert medications by the Institute for Safe Medication Practices (ISMP).

In congenital heart disease pathways, thrombosis risk can be amplified by turbulent or restricted blood flow, blood stasis, heart-failure burden, rhythm disorders, polycythemia-related hyperviscosity, central venous catheters/shunts, and cardiopulmonary-bypass exposure during surgery.

In pediatric pulmonary-hypertension pathways, routine anticoagulation is not universal. Teams may avoid it when hemorrhage risk is high, and if selected, use low-dose regimens with strict bleeding surveillance.

In pregnancy and postpartum VTE care, LMWH is commonly the first-line option when anticoagulation is not contraindicated. Warfarin and other oral anticoagulants are generally avoided during pregnancy due to fetal risk, and labor/delivery timing requires coordinated bleeding-risk planning. When anticoagulation is contraindicated in pregnancy/postpartum DVT, invasive prevention pathways such as IVC filter placement may be used.

Major Anticoagulant Classes

Injectable Anticoagulants

Heparin (Unfractionated Heparin — UFH)

Mechanism: Binds antithrombin → inactivates coagulation factors IIa (thrombin), Xa, IXa, XIa, XIIa → prevents fibrin clot formation. Does NOT have fibrinolytic activity.

Routes: Intravenous (treatment) or subcutaneous (prophylaxis). Oral route is ineffective.

Indications: DVT/PE treatment, acute MI, prevention of DVT in immobilized patients, maintaining central line patency (heparin flush).

Monitoring: aPTT (goal: 1.5–2.5× normal baseline). Monitor every 6 hours during IV infusion. Institutional weight-based protocols guide dose titration.

Reversal Agent: Protamine sulfate (slow IV infusion).

Key Safety Issues:

• Fatal medication errors have occurred — verify product and dose carefully before administration
• UFH concentration mix-ups are a known severe-error pathway; use concentration-specific checks and dedicated heparin syringe processes per policy when withdrawing from vials
• Risk of heparin-induced thrombocytopenia (HIT): platelet drop ≥30% below baseline → discontinue immediately
• HIT can progress to HITT (HIT + thrombosis) — paradoxical clotting despite anticoagulation
• Higher bleeding risk in patients >60 years, especially women
• For SQ heparin, rotate sites, prefer abdominal adipose tissue at least about 2 in (5 cm) from umbilicus, inject at about 90 degrees slowly, and do not massage post-injection to reduce hematoma risk
• Reassess bleeding-risk comorbidities and interacting agents (for example aspirin/NSAIDs and certain herbals) before each dose

Low-Molecular Weight Heparin (LMWH) — Enoxaparin (Lovenox)

Mechanism: Higher anti-Xa to anti-IIa ratio than UFH → more predictable anticoagulation.

Route: Subcutaneous injection; prefer abdominal site for best absorption.

Advantage: Does NOT require routine PTT monitoring; predictable pharmacokinetics allow fixed or weight-based dosing.

Reversal Agent: Protamine sulfate (partial reversal only).

LMWH Boxed Warning — Spinal Hematoma

Epidural or spinal hematomas may occur in patients anticoagulated with LMWH undergoing neuraxial anesthesia or spinal puncture. Risk of long-term or permanent paralysis. Monitor frequently for signs of neurological compromise.

Oral Anticoagulants

Warfarin (Coumadin)

Mechanism: Inhibits vitamin K-dependent clotting factors (II, VII, IX, X) and anticoagulant proteins C and S.

Onset: Delayed — 2–5 days to therapeutic effect (existing clotting factors must be depleted).

Monitoring: INR (prothrombin time normalized ratio).

• Normal INR (no anticoagulation): 1.0
• Therapeutic INR for most indications: 2.0–3.0
• Mechanical heart valves: may require INR 2.5–3.5

Reversal Agent: Vitamin K (oral or IV); fresh frozen plasma (FFP) for urgent reversal.

Critical Drug-Food Interactions:

• Increases warfarin effect (↑ bleeding risk): Alcohol, cranberries, grapefruit
• Decreases warfarin effect (↓ therapeutic efficacy): Vitamin K-rich foods (green leafy vegetables — eat consistently, do not avoid entirely)
• Significant interactions with hundreds of medications — always review drug label

Bridging Therapy: When transitioning from IV heparin to warfarin, both drugs overlap until INR reaches therapeutic range; then heparin is discontinued.

Contraindications: Pregnancy (fetal harm — use only for mechanical heart valves if essential after specialist risk-benefit review); active bleeding; recent CNS or eye surgery.

Warfarin Boxed Warning — Major or Fatal Bleeding

Warfarin can cause major or fatal bleeding. Perform regular INR monitoring. Dietary changes, illness, and drug interactions significantly affect INR. Instruct patients on bleeding prevention and to report any signs of bleeding immediately.

Direct Oral Anticoagulants (DOACs)

Advantage over warfarin: No routine laboratory monitoring required; fewer drug-food interactions; predictable pharmacokinetics.

Drug	Mechanism	Reversal Agent
Rivaroxaban (Xarelto)	Selective factor Xa inhibitor	Andexxa (andexanet alfa)
Apixaban (Eliquis)	Selective factor Xa inhibitor	Andexxa
Dabigatran (Pradaxa)	Direct thrombin inhibitor	Praxbind (idarucizumab)

Indications: DVT/PE prevention and treatment, stroke prevention in atrial fibrillation, cardiovascular risk reduction in CAD/PAD.

Cautions: Reduce dose or avoid in renal impairment (especially dabigatran); avoid in severe liver impairment (rivaroxaban, apixaban).

Nursing Assessment

Before Administration:

• Verify indication and current monitoring parameters (INR for warfarin, aPTT for heparin)
• Check for active bleeding, recent surgery, or fall risk
• Review all concurrent medications and supplements for interactions
• Perform independent double-check (ISMP requirement for high-alert medications)

Ongoing Monitoring:

• Signs of bleeding: Unusual bruising, petechiae, blood in urine/stool, decreased BP with elevated HR (internal hemorrhage), prolonged bleeding from cuts
• Platelet count for heparin-exposed patients (HIT screening)
• Neuro checks for spinal anesthesia patients on LMWH
• INR/aPTT results within therapeutic range before each dose

Patient Education:

• Use electric razor instead of straight blade; soft toothbrush
• Bleeding precautions: avoid IM injections, contact sports
• Warfarin: take at the same time daily; consistent vitamin K intake; report to all providers and dentists; carry anticoagulant ID card
• Report any unusual bleeding, bruising, or signs of stroke/PE immediately
• Do NOT stop anticoagulants without provider guidance

Related Concepts

• hemostasis-coagulation-and-fibrinolysis — Coagulation cascade that anticoagulants target
• deep-vein-thrombosis — Primary clinical indication for anticoagulation
• systematic-ecg-interpretation-and-dysrhythmia-triage — Stroke prevention with anticoagulation
• high-alert-medications — Anticoagulants classified as ISMP high-alert drugs
• thrombocytopenia-bleeding-risk-and-management — HIT as a complication of heparin therapy
• antihypertensives — Concurrent cardiovascular medication management
• congenital-heart-defects-acyanotic-and-cyanotic-patterns — Structural lesions and postoperative pathways can increase thrombosis risk and anticoagulation complexity.

Self-Check

1. A patient is receiving IV heparin therapy. The aPTT result is 85 seconds (baseline 30 seconds). Is this therapeutic? What is the target range?
2. A patient on warfarin has an INR of 4.8 and is not bleeding. What is the appropriate nursing action?
3. After starting subcutaneous enoxaparin, a patient develops a platelet count drop from 200,000 to 120,000. What complication do you suspect, and what is the immediate action?